Holen Sie sich die Stockscreener-App
79.75
1.09%
0.62
Schlusskurs vom Vortag:
$79.13
Offen:
$79.38
24-Stunden-Volumen:
264.27K
Relative Volume:
0.47
Marktkapitalisierung:
$5.71B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-20.45
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
+6.65%
1M Leistung:
+10.68%
6M Leistung:
-0.39%
1J Leistung:
+3.92%
1-Tages-Spanne:
$78.93
$80.08
1-Wochen-Bereich:
$74.31
$80.05
52-Wochen-Spanne:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Vergleichen Sie NUVL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
79.75 | 5.71B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.12 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.65 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.02 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.73 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.84 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Nuvalent appoints former Genentech oncology executive to board - Investing.com
Nuvalent appoints Christy Oliger to board of directors - MarketScreener
Nuvalent Adds Former Genentech Oncology SVP to Board Ahead of 2026 Launch Plans | NUVL Stock News - Stock Titan
Nuvalent’s SWOT analysis: biotech stock poised for pivotal year in NSCLC treatment - Investing.com
GAMMA Investing LLC Boosts Stake in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
(NUVL) Long Term Investment Analysis - news.stocktradersdaily.com
Rhumbline Advisers Acquires 2,572 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent’s SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stock By Investing.com - Investing.com South Africa
Nuvalent’s SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stock - Investing.com India
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results - Seeking Alpha
Nuvalent board member Emily Conley resigns By Investing.com - Investing.com Nigeria
Nuvalent board member Emily Conley resigns - Investing.com
Nuvalent Board Member Emily Conley Resigns - TipRanks
How the (NUVL) price action is used to our Advantage - news.stocktradersdaily.com
Nuvalent, Inc. Reports Q1 2025 Financial Results - TipRanks
Nuveen Asset Management LLC Has $6.62 Million Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium - The Globe and Mail
Nuvalent (NUVL) Stock on the Rise: Decoding the 4.7% Surge and Price Potential - Daily Chhattisgarh News
Nuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal year By Investing.com - Investing.com Nigeria
Nuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal year - Investing.com Australia
Deutsche Bank AG Has $2.79 Million Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Shares Acquired by Bank of America Corp DE - Defense World
BNP Paribas Financial Markets Acquires Shares of 17,366 Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Shares Sold by Dimensional Fund Advisors LP - Defense World
A Bullish 2025 Outlook For Nuvalent Inc (NASDAQ: NUVL) Shares - Stocksregister
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Nuvalent (NUVL) Targets Key Milestones with Solid Financial Backing | NUVL Stock News - GuruFocus
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results - Quantisnow
Financial Health Check: Examining Nuvalent Inc (NUVL)’s Key Ratios - DWinneX
Nuvalent, Inc. (NASDAQ:NUVL) Stock Holdings Lowered by Envestnet Asset Management Inc. - Defense World
When the Price of (NUVL) Talks, People Listen - news.stocktradersdaily.com
Nuvalent Inc (NUVL) looking to reclaim success with recent performance - Sete News
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results - Seeking Alpha
Nuvalent reveals preclinical data on cancer drug zidesamtinib - Investing.com
Nuvalent Announces Publication in Molecular Cancer Therapeutics - GuruFocus
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PR Newswire
Indo-Asian News Service - Indo-Asian News Service (IANS)
Nuvalent, Inc. (NASDAQ:NUVL) Position Boosted by Wells Fargo & Company MN - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting - ADVFN
Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
Nuvalent describes new ROS and ALK tyrosine kinase receptor inhibitors - BioWorld MedTech
UBS gives a Buy recommendation for Nuvalent Inc (NUVL) - knoxdaily.com
JPMorgan Chase & Co. Acquires 47,818 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Trend Tracker for (NUVL) - news.stocktradersdaily.com
Nuvalent Board Member Resigns, Joins Advisory Board - TipRanks
Alliancebernstein L.P. Purchases 500 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Commonwealth Equity Services LLC Raises Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Sei Investments Co. Reduces Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvalent Inc-Aktie (NUVL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Porter James Richard | President and CEO |
Jun 16 '25 |
Option Exercise |
27.85 |
27,000 |
751,950 |
276,062 |
| Porter James Richard | President and CEO |
Jun 16 '25 |
Sale |
76.93 |
27,000 |
2,077,093 |
249,062 |
| Pelish Henry E. | Chief Scientific Officer |
Jun 06 '25 |
Option Exercise |
28.59 |
200 |
5,718 |
63,301 |
| Pelish Henry E. | Chief Scientific Officer |
Jun 06 '25 |
Sale |
79.82 |
200 |
15,964 |
63,101 |
1.37%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):